Your browser doesn't support javascript.
Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups.
Yale, Jean-François; Bodholdt, Ulrik; Catarig, Andrei-Mircea; Catrina, Sergiu; Clark, Alice; Ekberg, Neda Rajamand; Erhan, Umut; Holmes, Patrick; Knudsen, Søren Tang; Liutkus, Joanne; Sathyapalan, Thozhukat; Schultes, Bernd; Rudofsky, Gottfried.
  • Yale JF; Royal Victoria Hospital, McGill University Health Centre, Montreal, Quebec, Canada jean-francois.yale@mcgill.ca.
  • Bodholdt U; Kastruplægerne, Kastrup, Denmark.
  • Catarig AM; Novo Nordisk AS, Søborg, Denmark.
  • Catrina S; Karolinska Institutet, Stockholm, Sweden.
  • Clark A; Center for Diabetes, Academic Specialist Center, Stockholm, Sweden.
  • Ekberg NR; Novo Nordisk AS, Søborg, Denmark.
  • Erhan U; Karolinska Institutet, Stockholm, Sweden.
  • Holmes P; Novo Nordisk AS, Søborg, Denmark.
  • Knudsen ST; St. George's Medical Practice, Darlington, UK.
  • Liutkus J; Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark.
  • Sathyapalan T; Joanne F. Liutkus Medicine Professional Corporation, Cambridge, Ontario, Canada.
  • Schultes B; Academic Diabetes, Endocrinology and Metabolism, University of Hull, Hull, UK.
  • Rudofsky G; Metabolic Center St. Gallen, friendlyDocs, St. Gallen, Switzerland.
BMJ Open Diabetes Res Care ; 10(2)2022 04.
Article in English | MEDLINE | ID: covidwho-1779347
ABSTRACT

INTRODUCTION:

This post hoc pooled analysis of four real-world studies (SURE Canada, Denmark/Sweden, Switzerland and UK) aimed to characterize the use of once-weekly (OW) semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), in patients with type 2 diabetes (T2D). RESEARCH DESIGN AND

METHODS:

The Semaglutide Real-world Evidence (SURE) studies had a duration of ~30 weeks. Changes in glycated hemoglobin (HbA1c) and body weight (BW) were analyzed for the overall population and the following baseline subgroups GLP-1RA-naïve/GLP-1RA switchers; body mass index <25/≥25-<30/≥30-<35/≥35 kg/m2; age <65/≥65 years; HbA1c <7%/≥7-≤8%/>8-≤9%/>9%; T2D duration <5/≥5-<10/≥10 years. Data for patients achieving treatment targets were analyzed in the overall population and the baseline HbA1c ≥7% subgroup.

RESULTS:

Of 1212 patients, 960 were GLP-1RA-naïve and 252 had switched to semaglutide from another GLP-1RA. In the overall population, HbA1c was reduced from baseline to end of study (EOS) by -1.1% point and BW by -4.7 kg; changes were significant for all subgroups. There were significantly larger reductions of HbA1c and BW in GLP-1RA-naïve versus GLP-1RA switchers and larger reductions in HbA1c for patients with higher versus lower baseline HbA1c. At EOS, 52.6% of patients in the overall population achieved HbA1c <7%. No new safety concerns were identified in any of the completed SURE studies.

CONCLUSIONS:

In this pooled analysis, patients with T2D initiating OW semaglutide showed significant improvements from baseline to EOS in HbA1c and BW across various baseline subgroups, including patients previously treated with a GLP-1RA other than semaglutide, supporting OW semaglutide use in clinical practice. TRAIL REGISTRATION NUMBERS NCT03457012; NCT03631186; NCT03648281; NCT03876015.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 Type of study: Observational study / Prognostic study / Reviews Limits: Aged / Humans Language: English Year: 2022 Document Type: Article Affiliation country: Bmjdrc-2021-002619

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 Type of study: Observational study / Prognostic study / Reviews Limits: Aged / Humans Language: English Year: 2022 Document Type: Article Affiliation country: Bmjdrc-2021-002619